key: cord-0776033-jb20w48y
authors: Dey-Rao, Rama; Smith, George R.; Timilsina, Uddhav; Falls, Zackary; Samudrala, Ram; Stavrou, Spyridon; Melendy, Thomas
title: A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition
date: 2021-10-07
journal: Antiviral Res
DOI: 10.1016/j.antiviral.2021.105183
sha: 500f4f5e9c012fd83c3a6566309dd9a63d0d64fe
doc_id: 776033
cord_uid: jb20w48y

The likelihood of continued circulation of COVID-19 and its variants, and novel coronaviruses due to future zoonotic transmissions, combined with the current paucity of coronavirus antivirals, emphasize the need for improved screening in developing effective antivirals for the treatment of infection by SARS-CoV-2 (CoV2) and other coronaviruses. Here we report the development of a live-cell based assay for evaluating the intracellular function of the critical, highly-conserved CoV2 target, the Main 3C-like protease (Mpro). This assay is based on expression of native wild-type mature CoV2 Mpro, the function of which is quantitatively evaluated in living cells through cleavage of a biosensor leading to loss of fluorescence. Evaluation does not require cell harvesting, allowing for multiple measurements from the same cells facilitating quantification of Mpro inhibition, as well as recovery of function upon removal of inhibitory drugs. The pan-coronavirus Mpro inhibitor, GC376, was utilized in this assay and effective inhibition of intracellular CoV2 Mpro was found to be consistent with levels required to inhibit CoV2 infection of human lung cells. We demonstrate that GC376 is an effective inhibitor of intracellular CoV2 Mpro at low micromolar levels, while other predicted Mpro inhibitors, bepridil and alverine, are not. Results indicate this system can provide a highly effective high-throughput coronavirus Mpro screening system.

A total of 150,000 or 50,000 AD293 cells were seeded in 24-well and 96-well plates, 144 respectively, and maintained in a humidified tissue culture incubator at 37˚C in a 5% CO2 145 atmosphere to 80-90% confluency. Triplicate wells were either left untransfected or were 146 transfected in serum free OPTIMEM, using Lipofectamine 2000 with indicated vector constructs. were still produced (Fig 1B, lane 3) , consistent with findings for other CoV Mpro enzymes (34-208 36). When C145, (critical for Mpro's catalytic function (37)), was mutated to alanine (C145A) 209 predictably the enzyme was inactive and unable to cleave the AVLQS sequence, resulting in the 210 GST-Mpro fusion protein, and no cleaved GST (Fig 1B, lane 4) Fig 1) . The AVLQS sequence has also been 224 shown to be efficiently cleaved in vitro by various recombinant CoV Mpros, including CoV2 Mpro 225 (34, 35, 37, 40) . When either the parental, or the pRFP-AVLQS vector (Fig 2B) were transfected 226 into HEK293T cells, each produced the predicted (~54kDa) RFP protein, as well as lower levels 227 of a lightly smaller breakdown product (~40kDa) (Fig 2C) 

Quantification of the fluorescence in all the panels of Figure 3C is shown in Figure 3D .

It is important to recognize that the RFP fluorescence is not merely positive or negative, but 251 can be detected at varying levels that can be quantified. The two plasmids (Fig 1A & Fig 2B) in 252 these assays were used at a ratio of 1:4 of (pGST-Mpro/pRFP-AVLQS). By quantifying levels of CoV2 Mpro is an excellent target for CoV2 antivirals; hence, much effort has been directed at 305 identifying and testing existing drugs that could be repurposed for use against Mpro for the 306 COVID-19 pandemic (37, 41, 42, 44, (46) (47) (48) (49) (50) (51) . However, these approaches rarely demonstrate that 307 these drugs will inhibit Mpro function in living cells. The assay above was used to evaluate two 308 of the drugs from the panel of FDA-approved drugs and bioactive compounds that we previously 309 predicted to target CoV2 Mpro with some of the highest predicted affinities (52). One of these 310 drugs, Bepridil, has been shown to inhibit purified CoV2 Mpro in vitro (53). Using the 311 computational drug-protein interaction program, CANDOCK (54,55), these two drugs, Alverine 312 and Bepridil, as well as GC376 were docked onto the CoV2 Mpro structure (56). Each drug was 313 predicted to bind CoV2 Mpro, and each docked into the active site pocket of the enzyme, that 314 contains a highly nucleophilic catalytic cysteine residue (53), with predicted relative binding 315 scores of -69.4, -71.3, and -93.4, respectively (Fig 6A) . Using this assay, we tested the ability of 316 these drugs to inhibit intracellular CoV2 Mpro function; the drugs were evaluated at high, but 317 non-toxic drug levels (100µM), every hour over an 18 hr time course (Fig 6B) . Bepridil showed 318 no inhibition of intracellular CoV2 Mpro activity as compared to GC376, which resulted in a 319 dramatic increase in fluorescence levels between hours 8 and 18 (Fig 6B, compare triangles to 320 circles). Alverine, which was suggested to potentially inhibit CoV2 Mpro based on predicted (52), are predicted to have 328 lower affinity than GC376 (Fig 6A) , and to not be effective in inhibiting intracellular Mpro ( fluorescence are seen (Fig 7A hatched bars) , while the cells remain viable (Fig 7A triangles) .

(The cultures treated with 100 µM GC376 retained fairly high RFP signal. This is likely due to 349 levels of GC376 sufficient for Mpro inhibition remaining in the wells after media exchange. The

J o u r n a l P r e -p r o o f wells were not rinsed to remove residual drug to prevent dislodging the cultured cell layer.) To 351 evaluate the time-dependence of this recovery GC376 was used at 10 µM and fluorescence 352 was quantified at every hour during both drug treatment as well as after removal. Following 353 removal of the GC376, fluorescence levels decreased over the first 2 to 3 hours (Fig 7B) . Loss 354 of fluorescence corresponds to loss of the RFP 54 kDa protein (Fig 7C) . After 17h treatment 355 with 0.01-100 M GC376 (Fig 7C, 

The cleavage of the previously accumulated 54 kDa was also evident by increased levels of the 363 27 kDa Mpro-cleaved polypeptides in extracts from cells previously treated with the higher 364 levels of GC376. These conclusions were consistent with loss of the "drug-protected" GST-3CL 365 fusion protein (in 10 and 100 µM treated cultures) following drug removal (Supplemental Fig 6) 

It has been noted that RdRps and viral proteases are both excellent targets for CoV antivirals 382 (20, 22, 23, 47) . Indeed, for other viruses that require both a viral polymerase and a protease to 

Many drugs and compounds have been evaluated as potential inhibitors of CoV2 Mpro using 393 computational prediction programs, and some of these have been tested for function against 394 CoV2 Mpro, generally against purified CoV2 Mpro (15, 41, 42, 46, 47, [50] [51] [52] 57, 60, 68, 72) , but this 395 does not ensure that the drug will be effective intracellularly (73). For example, our finding that 396 Ebselen was not effective in this intracellular assay may be due to issues related to the 

which provides for less-than-facile screening (77). Also, a GFP-based CoV2 Mpro assay has 410 been reported which functions in the reverse direction from the RFP system described herein -

Mpro cleavage of their recombinant GFP protein allows the two GFP domains to associate and 412 to produce green fluorescence signal (78). This GFP system does exhibit some of the 413 advantages we describe above for the RFP system. However, when using these systems for 414 high-throughput screening, the RFP system we describe here is superior to the GFP system Mpro with a non-native N-terminus, which is known to compromise Mpro activity (34). It is 429 anticipated that this system will not only prove highly useful as a screening system for inhibitors 430 of CoV2 Mpro, but will be readily adaptable to other CoV Mpro enzymes, as well as other viral 431 and even cellular proteases. This system can also be utilized for analyzing protease function to Fig 3F) . B) Images shown are from hour 36, or 15 hrs after addition of drug/OPTIMEM), 751 visualizing for RFP (even panels) or RFP and DNA (odd panels), using the Cytation 1 imaging 752 reader as described above. Bar =1000 m. 

The hierarchical fragment-based docking with dynamics protocol (CANDOCK) (55) was used to 772 determine the predicted docking of two existing drugs (from the FDA approved drugs library) 773 among those predicted to have the highest affinity to CoV2 Mpro (52), Alverine and Bepridil, as 774 well as GC376, onto one of the earliest deposited crystal structures of Mpro (pdb 6Y2e) (56).

The site on CoV2 Mpro that each drug was predicted to bind to was the catalytic pocket of CoV2 776 Mpro (53). The relative binding scores for each predicted interaction is presented, with Alverine 

Percent inhibition (y axis) was determined throughout the 17 hrs of GC376 treatment, followed 800 by 23 hrs of recovery after drug removal. C) Extracts from AD293 cells in 7A were 801 immunoblotted for RFP after the 17 hr drug treatment (left panels) and after the 23 hr of 802 recovery after removal of GC376 (right panels). Beta actin verified consistent levels of extract 803 J o u r n a l P r e -p r o o f for each lane (lower panels). Immunoblotting for GST and GST-Mpro for these cultures provided

Ebsulfur and Ebselen as highly potent scaffolds for the development 624 of potential SARS-CoV-2 antivirals

Identifying SARS-CoV-2 antiviral 627 compounds by screening for small molecule inhibitors of Nsp5 main protease

High-Throughput Screening for 630 Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor

N-Terminal Finger Stabilizes the S1 633 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M(pro) Dimer

Dexamethasone in Hospitalized 639 Patients with Covid-19 -Preliminary Report

Dexamethasone in the management of covid -19

High dose dexamethasone treatment for Acute Respiratory 644 Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for 645 a randomised controlled trial

Corticosteroids in COVID-19 ARDS: Evidence and 647 Hope During the Pandemic

Efficacy of dexamethasone 650 treatment for patients with the acute respiratory distress syndrome caused by COVID-651 19: study protocol for a randomized controlled superiority trial

Remdesivir, lopinavir, emetine, and 654 homoharringtonine inhibit SARS-CoV-2 replication in vitro

SARS-CoV-2 immune evasion by 657 the B.1.427/B.1.429 variant of concern

High-Throughput Screening and Identification of Potent Broad-Spectrum 662 Inhibitors of Coronaviruses

Lack of Effectiveness of Repurposed Drugs for COVID-19

666 (2021) Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal 667 antiserum and a luciferase-based biosensor

Development of a Cell-Based Luciferase Complementation Assay for Identification of 670 SARS-CoV-2 3CL(pro) Inhibitors. Viruses

A simplified cell-based assay to identify coronavirus 3CL 673 protease inhibitors. bioRxiv

Gain-of-function assay for SARS-CoV-2 M (pro) inhibition in living cells. bioRxiv

High-Throughput SARS-CoV-2 3CL(pro) Reporter Assay

in Supplemental Figure 6 are consistent with the cleavage results for RFP ( Fig 7C) . 

3D were subjected to SDS-PAGE and immunoblotting for RFP (as in Fig 2C) (A) and observed 835 by microscopy for phase contrast and fluorescence (as in Fig 3C) 

Cytation 1 system (as described in the Methods and legend to Fig 3E) . Images were captured at 863 the 36 th hr (Fig 3E) , Hoechst-stained DNA was imaged using the Cytation 1 DAPI 864 (Ex377/Em447) and RFP (Ex531/ Em593) filters, producing blue and orange colors, 

(4), Alverine (5) or Ebselen (6) in OPTI-MEM with 5% DMSO for 18 hrs showed that Alverine or

Bepridil treatment showed little increase in RFP signal compared to the control (right panels of 4 891 and 5 compared to 3). There was no apparent fluorescence to explain the immediate increase in 892 basal levels of fluorescence upon Alverine addition, seen in the quantitative analysis ( Fig 6D) .

Ebselen also did not increase red fluorescence (6, right); albeit treatment of these levels of 

The same extracts as those in Figure 7C were subjected to immunoblotting for GST to evaluate 911 GST-Mpro expression and self-cleavage during GC376 treatment followed by drug removal and 912 recovery. Extracts were immunoblotted for GST at two points: after the 17 hr drug treatment (left 913 panels), and then again after the 23 hr of recovery after removal of GC376 (right panels). In the